DEO vs STZ: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: STZ is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. DEO and STZ share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined DEO and STZ exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Diageo plc is the largest spirits producer in the world by value, selling in roughly 180 markets from a portfolio that spans Johnnie Walker, Buchanan's and other Scotch, Smirnoff and Ketel One vodka, Tanqueray and Gordon's gin, Captain Morgan rum, Crown Royal Canadian whisky, Bulleit bourbon, Baileys, the Don Julio and Casamigos tequilas, and Guinness stout. It also holds controlling stakes in listed subsidiaries including United Spirits in India, and has been reshaping the edges of the group: East Africa Breweries is being sold with completion expected in calendar H2 2026, and United Spirits is divesting the Royal Challengers Bengaluru cricket franchise. The economics are those of a branded-goods owner rather than a manufacturer, with pricing power, long aging cycles for whisky and tequila that tie up working capital, and distribution scale that is hard to replicate.

Full DEO guide

Constellation Brands is a producer, marketer, and distributor of beer, wine, and spirits, best known for holding the US rights to Mexican import beers including Corona, Modelo Especial, and Pacifico. Beer is the economic engine: it drives the large majority of both net sales and operating income, and Modelo Especial has been one of the top-selling beer brands in the US. The wine and spirits segment is far smaller and has been contracting, partly by design after the company divested lower-priced wine brands (including SVEDKA and a 2025 wine portfolio sale) to concentrate on higher-margin labels.

Full STZ guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• DEO drivers: The cost program and margin defence; Deleveraging and the reset dividend.
• STZ drivers: Imported beer franchise; Cash generation and buybacks.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The core risk is that the spirits downturn is structural rather than cyclical: US consumption has been falling since the post-pandemic peak, and moderation trends among younger drinkers, GLP-1 weight-loss drugs and cannabis substitution are all cited as reasons the volume base may not recover to prior trend. For STZ, the largest risk is US tariffs on Mexican imports: because the bulk of Constellation's beer is brewed in Mexico, tariff changes can meaningfully pressure margins and earnings, and management has flagged a potential multi-dollar per-share EPS headwind.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick DEO if you believe its drivers more; STZ if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the DEO and STZ guides.

DEO. At roughly $94 per ADR against ~$6.61 of ADR-equivalent earnings before exceptional items, DEO trades near ~14x, well below the 20x-plus multiple it carried through the 2010s and much of the pandemic era. The reported figure looks very different: basic EPS of ~78.1 cents (~$3.12 per ADR) reflects ~$1.5 billion of impairments and ~$0.9 billion of restructuring, so the headline P/E on statutory earnings is roughly double. Enterprise value including ~$20.5 billion of net debt is around $73 billion, or roughly 11x adjusted EBITDA.

STZ. Figures are approximate and drawn from mid-2026 market data and the company's fiscal 2026 disclosures. The low-teens earnings multiple sits well beneath STZ's multi-year historical range, reflecting tariff and demand concerns. Reported net income can be distorted in periods with large non-cash wine and spirits impairments, so free cash flow is often a cleaner read on the business.

Headline figures (approximate, August 2026): DEO shows net sales (fy2026) ~$19.6B, -3.0% reported, -2.0% organic, operating profit (before exceptionals) ~$5.7B, ~28.9% margin, eps before exceptional items ~165.3c per share (~$6.61 per ADR), free cash flow (fy2026) ~$3.2B; STZ shows market cap ~$25B, share price ~$130, p/e (trailing) ~13, fy2026 operating cash flow ~$2.67B.

DEO and STZ are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined DEO and STZ exposure against your real portfolio. It is not an investment adviser.